In 2014, Governor Andrew Cuomo backed a community advocated plan to aggressively scale up testing, linkage to treatment, and PrEP access in order to dramatically reduce new infections below epidemic levels by the year 2020. The good news is that…
Bend the Curves: Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible.
By Suraj Madoori During Trump’s first-ever State of the Union address on January 30, activists observed a dearth of clear priorities to eliminate HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the U.S. Science and longstanding bipartisan interest in…
By Jeremiah Johnson The December 2017 release of the New York State (NYS) 2016 HIV/AIDS surveillance data shows that the efforts to End the Epidemic (EtE) in New York are having an impact. In 2014, Governor Andrew Cuomo backed a…
Slide decks for the Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV.
Introduction For many HIV-positive people—particularly those who initiate treatment soon after infection—combination antiretroviral therapy (ART) is associated with robust improvements in CD4+ T cell counts, enhanced immune function, and a life expectancy comparable to that of similar HIV-negative individuals. But a…
Pregnant women have frequently been excluded from or de-prioritized in clinical research initiatives due to a multitude of factors, such as the complex physiology of pregnant women, the risk studies may pose to the fetus, and the classification of pregnant…
The purpose of this Training Manual is to provide information for you and your community. This information can be used to advocate for access to prevention and diagnosis of, and care and treatment for, hepatitis C virus (HCV). The manual is written by and for people who are not medical specialists. We’re treatment activists who learned about HCV because it was a problem for people in our communities.
Gilead Sciences is limiting access to Truvada as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by uninsured and underinsured U.S. residents.
TAG mourns the loss of an inspirational, tireless, catalytic leader of our movement. Dr. Krim understood the gravity of the epidemic, in its earliest and darkest days, and was driven by her own remarkable intelligence, fierce commitment to civil rights and social justice, extraordinary social and political networks, and true grit to galvanize funders, scientists, policy leaders, and activists toward a single cause: ending HIV and AIDS as a threat to humanity.